We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Clavis Pharma Licenses LVT Compound CP-4033 to Translational Therapeutics for Development in Aggressive Thyroid Tumours

News   Jun 06, 2011

 
Clavis Pharma Licenses LVT Compound CP-4033 to Translational Therapeutics for Development in Aggressive Thyroid Tumours
 
 
 

RELATED ARTICLES

For the First Time, Astronauts Edit Genes in Space

News

For the first time, astronauts have used CRISPR/Cas9 technology to edit DNA in space. The gene editing technique was deployed on the International Space Station (ISS) to induce targeted breaks in the yeast genome.

READ MORE

New Exercise Guidelines for Cancer Patients

News

A decade-old treatment recommendation for people with cancer to take a "slowly slowly" approach to exercise has been replaced with new guidelines recommending a personalized exercise program.

READ MORE

Are Transplanted Stem Cells Healing the Target Organ? Perhaps Ask the Exosomes

News

While many regenerative medicine applications are being pursued, the ability to track cells after transplant and determine their therapeutic efficacy is a challenge. Could exosomes, circulating cell-derived vesicles, hold the key?

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE